Although metabolic syndrome is associated with higher PsA disease activity, it is not associated with higher PsA-related ...

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...

Bristol-Myers Squibb (BMY) stock in focus as psoriasis drug Sotyktu shows promising results in treating psoriatic arthritis ...

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed ...

Overactive bladder (OAB) is associated with arthritis, with a positive association seen after adjustment for all covariates.

The following is a summary of “Potentially Avoidable Emergency Department Utilization by Persons With Psoriatic Arthritis and ...

Rebecca Haberman, MD, of NYU Langone Health, highlights precision medicine and potential prevention strategies, two areas of promising psoriatic arthritis research.

Patients with hidradenitis suppurativa are at increased risk of developing several common inflammatory arthropathies in the years following diagnosis.

Bristol Myers Squibb's Phase 3 POETYK PsA-2 trial shows Sotyktu improved psoriatic arthritis symptoms, meeting primary and secondary endpoints at Week 16.

The global Psoriatic Arthritis (PsA) Treatment Market is expected to grow from USD 11,973.7 million in 2024 to USD 25,375.6 ...

Biologic disease-modifying antirheumatic drugs (bDMARDs) do not appear to negatively impact fertility among women with rheumatoid arthritis (RA) or psoriatic arthritis (PsA), according to study ...